A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Jose Mauricio Mota 1 , Katharine Ann Collier 3 , Ricardo Lima Barros Costa 2 , Timothy Taxter 2 , Aparna Kalyan 2 , Caio A. Leite 4 , Young Kwang Chae 2 , Francis J. Giles 2 and Benedito A. Carneiro 2 1 Instituto do Câncer do Estado de São Paulo, Division of Oncology, Universidade de São Paulo, São Paulo, Brazil 2 Developmental Therapeutics Program, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA 3 Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA 4 Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil Correspondence to: Benedito A. Carneiro, email: // Keywords : heregulins, HER3, HER4, cancer, developmental therapeutics Received : March 19, 2017 Accepted : April 17, 2017 Published : June 13, 2017 Abstract Heregulins (HRGs) bind to the receptors HER3 or HER4, induce receptor dimerization, and trigger downstream signaling that leads to tumor progression and resistance to targeted therapies. Increased expression of HRGs has been associated with worse clinical prognosis; therefore, attempts to block HRG-dependent tumor growth have been pursued. This manuscript summarizes the function and signaling of HRGs and review the preclinical evidence of its involvement in carcinogenesis, prognosis, and treatment resistance in several malignancies such as colorectal cancer, non-small cell lung cancer, ovarian cancer, and breast cancer. Agents in preclinical development and clinical trials of novel therapeutics targeting HRG-dependent signaling are also discussed, including anti-HER3 and -HER4 antibodies, anti-metalloproteinase agents, and HRG fusion proteins. Although several trials have indicated an acceptable safety profile, translating preclinical findings into clinical practice remains a challenge in this field, possibly due to the complexity of downstream signaling and patterns of HRG, HER3 and HER4 expression in different cancer subtypes. Improving patient selection through biomarkers and understanding the resistance mechanisms may translate into significant clinical benefits in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B., & Yarden, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90131-u · Cited by 524 · cited 2×
“A 44-kDa glycoprotein, later to be classified as an HRG, was isolated and cloned from RAS-transformed rat fibroblasts in 1992.[3] The protein named Neu differentiation factor induced phosphorylation of p185neu (later called HER2/neu) and differentiation of human breast cancer cells.”
BackgroundOncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3145 · Cited by 264 · cited 4×
“[109] In preclinical models of lung cancer and HNSCC, seribantumab decreased HER3 phosphorylation.[109, 110] A preclinical animal model of ovarian cancer treated with seribantumab also showed decreased tumor growth.”
BackgroundInfluentialWilson, T. R., Lee, D. Y., Berry, L., Shames, D. S., & Settleman, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.07.011 · Cited by 161 · cited 1×
“Increased NRG1 and phosphorylated HER3 levels were associated with increased lapatinib sensitivity.[53]”
BackgroundHER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation
Vaught, D. B., Stanford, J. C., Young, C., Hicks, D. J., Wheeler, F., Rinehart, C., Sánchez, V., Koland, J., Muller, W. J., Arteaga, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3594 · Cited by 129 · cited 1×
“[69–72] In HER2-amplified breast cancers, HER3 is the preferential partner for dimer formation.[73, 74] HER3 mutations are common in lobular invasive breast cancer.”
BackgroundJuric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2412 · Cited by 59
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Epidermal growth in CRC, and its EGFR signaling amphiregulin ( transautophos-phorylation [26 HER4/ERBB4 heterodimers is pathways collectively promote binding promotes HER2/HER3 and HER3/HER4 heterodimers are tumor promoting [27].”
BackgroundThe Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70
“…Tumor Suppressor and an Oncoprotein associated with more aggressive colorectal tumors, particularly metastatic behavior (Kountourakis et al., 2006; Baiocchi et al., 2009; Frey et al., 2010; Khelwatty et al., 2013; Mitsui et al., 2014; Williams et al., 2015; Mota et al., 2017; Segers et al., 2020).”
BackgroundHER3 Is an Actionable Target in Advanced Prostate Cancer
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3360 · Cited by 68
“Ligand-induced activation of HER3 by neuregulins plays a key role in driving proliferation in HER3-positive tumors and has been recently suggested to play a role in prostate cancer biology in a subpopulation of prostate cancer (35).”
BackgroundThe Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J. (2022) · Cancers · doi:10.3390/cancers14092144 · Cited by 27
Metadata
- Authors
- Mota, J. M., Collier, K. A., Barros Costa, R. L., Taxter, T., Kalyan, A., Leite, C. A., Chae, Y. K., Giles, F. J., & Carneiro, B. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-06-13
- Volume
- 8
- Issue
- 51
- Pages
- 89284-89306
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2625993296
- Cited by
- 69
- References
- 7
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.